Highlights-
- Bharat Biotech International Limited has launched Nucelion Therapeutics, a wholly owned CRDMO focused on cell and gene therapies.
- The company has set up a state-of-the-art manufacturing facility in Genome Valley, designed for plasmids, viral vectors, and cell therapy production under global regulatory standards.
- Nucelion will provide comprehensive services—from early clinical development to large-scale commercial manufacturing—targeting treatments for cancer, autoimmune, and rare genetic diseases.
- The subsidiary will operate independently, collaborate with global biotech partners, and strengthen India’s position in the global biopharma and advanced therapy ecosystem.
Bharat Biotech International Limited, a global leader in vaccine research and biotechnology innovation, has announced the launch of Nucelion Therapeutics, a CRDMO for cell and gene therapies. The new venture is a wholly owned subsidiary of Bharat Biotech, reflecting the company’s vision to expand into advanced biological platforms and position India as a key player in the global biopharma ecosystem.
State-of-the-art facility in Genome Valley, Hyderabad
Located in Genome Valley, Hyderabad, Nucelion Therapeutics is equipped with a world-class GMP facility designed for the development and manufacturing of plasmids, viral vectors, and cell therapies. The CRDMO for cell and gene therapies will offer end-to-end solutions, from early-stage clinical development to large-scale commercial production, following international regulatory standards such as FDA and EMA guidelines.
Focus on next-generation therapies and innovation
According to Dr. Krishna Ella, Non-Executive Director of Nucelion Therapeutics, “The future of healthcare innovation lies in biological sciences. Our focus on a CRDMO for cell and gene therapies represents the next phase of transforming India’s healthcare landscape. These advanced therapies can offer hope for patients suffering from cancers, autoimmune disorders, and rare genetic diseases.”
Global partnerships and independent operations
Raghu Malapaka, Chief Business Officer of Nucelion Therapeutics, stated that the facility is built to serve both domestic and international clients. “By establishing a CRDMO for cell and gene therapies, Bharat Biotech aims to support global biotech innovators with scalable, high-quality, and regulatory-compliant manufacturing services,” he said.
Nucelion Therapeutics will function as an independent entity, maintaining its own leadership and governance systems while partnering with sponsors on commercial terms. The company has begun recruiting global talent with expertise in cell and gene therapy development, ensuring a strong foundation for operational excellence and scientific innovation.
Strengthening India’s biotech leadership
With the establishment of this CRDMO for cell and gene therapies, Bharat Biotech reinforces its commitment to advancing India’s biotechnology ecosystem. The new subsidiary positions the company at the forefront of next-generation medicine, driving progress in cell and gene therapy manufacturing, plasmid DNA production, and viral vector development.
.webp)